Expert Opinion on Drug Safety

Article	Citations
Novel insights into post-marketing AEs associated with bempedoic acid: a comprehensive analysis utilizing the FAERS database	108
The role of artificial intelligence in pharmacovigilance for rare diseases	84
Resistance to hedgehog inhibitors in basal cell carcinoma: strategies to adopt	81
Adverse event profiles of drug-induced decreased libido: an assessment of the US food and drug administration Adverse Event Reporting System	71
An update on the cognitive safety of antimuscarinics in the treatment of overactive bladder	57
Exploration and evaluation of adverse event signals of droxidopa based on the FAERS database	46
Assessment of adverse events of the novel antiepileptic drug lamotrigine: a real-world pharmacovigilance study based on FAERS	44
Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effects	44
Safety profile of isocitrate dehydrogenase inhibitors in cancer therapy: a pharmacovigilance study of the FDA Adverse Event Reporting System	42
Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the United States Food and Drug Administration Adverse Event Reporting Sys	41
Exploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database	39
A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting syst	32
Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment	30
Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study	29
An updated safety review of Hidradenitis Suppurativa treatment options	27
Mechanism and clinical utility of abatacept in the treatment of rheumatoid arthritis	27
Long-term safety of ketamine and esketamine in treatment of depression	26
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile	25
Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies: a systematic review and meta-analysis of observational studies	25
Drug-induced hepatitis B virus reactivation: insights from FAERS database analysis	24
Adverse events in patients with cardiovascular disease taking proton pump inhibitors	23
The safety of phthalate-containing medications used during pregnancy	23
The safety profile of azithromycin in pediatrics: a pharmacovigilance disproportionality analysis	22
Unveiling the hidden ocular risks of isotretinoin: a comprehensive FAERS-Based analysis	21
Pharmacovigilance approaches to study rare and very rare side-effects: the example of clozapine-related DiHS/DRESS syndrome	20

The Impact of Medication Regimen Complexity Score on Multi-Organ Dysfunction and Clinical Outcomes in Critically Ill Patients: A Cohort Study	20
A safety review of approved oral agents for treating type 2 diabetes and associated diseases in pregnant patients	19
Diarrhea-predominant irritable bowel syndrome treatment options eluxadoline, rifaximin, and alosetron: analysis of the FDA adverse event reporting system (FAERS) database	19
The effectiveness and safety of aripiprazole, bromocriptine, and cabergoline in the treatment of hyperprolactinemia: a systematic review and network meta-analysis	19
Safety concerns associated with BACE1 inhibitors – past, present, and future	17
Correction	17
Risk of acute kidney injury in patients receiving vancomycin and concomitant piperacillin-tazobactam or carbapenem: a multicenter, retrospective cohort study	17
Newly identified adverse events of enzalutamide using the food and drug administration adverse event reporting system	17
Safety evaluation of the DTaP5-IPV-Hib-HepB vaccine: a review	17
Safety and efficacy of anti-SARS-CoV-2 monoclonal antibodies in pregnancy	17
Does the use of generative AI chatbots by patients introduce risk of adverse drug events?	17
Proton pump inhibitors and increased reporting odds of renal neoplasms: FAERS-based adverse event data mining and analysis	17
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treat	16
Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study	16
Comparative disproportionality analysis of adverse events associated with combined therapy versus monotherapy of abiraterone and olaparib for prostate cancer: a pharmacovigilance study using the FAERS	16
A real-world disproportionality analysis of baloxavir marboxil: post-marketing pharmacovigilance data	15
Update of safety profile of levonorgestrel: a disproportionality analysis based on FAERS from 2004 to 2023	15
Corticosteroids for the treatment of Duchenne muscular dystrophy: a safety review	15
Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system	15
Long-term safety and effectiveness of vonoprazan for prevention of gastric and duodenal ulcer recurrence in patients on nonsteroidal anti-inflammatory drugs in Japan: a 12-month post-marketing surveil	15
Safety of intranasal corticosteroids for allergic rhinitis in children	14
Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system	14
Comparative analysis of CDKI-related adverse events in older patients: a real-world data from the FDA adverse event reporting system database	14
Post-marketing safety evaluation of zanubrutinib: a real-world pharmacovigilance analysis based on the FAERS database	14
Angioedema risk of thrombolytics: an integrated assessment using disproportionality analysis of the USFDA adverse event reporting system, case reviews and meta-analysis	14
Safety of current antiviral drugs for chronic hepatitis B	13
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study	13
Gastrointestinal adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the EudraVigilance and VigiAccess databases	13
Hallucinations and delusions associated with Parkinson’s disease psychosis: safety of current treatments and future directions	13
Data mining for signal detection of adverse events for taxanes based on the food and drug administration adverse drug events reporting system database	12
Drug-induced myocarditis: a real-world pharmacovigilance study using the FDA adverse event reporting system database	12
The use of hydroxyurea in the real life of MIOT network: an observational study	12
Vancomycin and linezolid: severe cutaneous adverse reactions to drugs	12
Development and validation of a nomogram to predict the risk of potentially inappropriate medication use in older lung cancer outpatients with multimorbidity	12
Tirzepatide and glucagon-like peptide-1 receptor agonists: safety always comes first!	12
Disproportionality analysis of the safety profile of rufinamide in the real world: an evaluation of the FDA Adverse Event Reporting System database	12
Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database	12
Long-term safety of lanthanum carbonate in the real word: a 19-year disproportionality analysis from the FDA Adverse Event Reporting System	12
Exploration of the clinical characteristics and potential mechanisms of liver injury induced by proton pump inhibitors	12
SSRI withdrawal syndrome in children and adolescents: a narrative literature review	12
Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system	12
Differences in safety profiles of anti-herpesvirus medications: a real-world pharmacovigilance study based on the FAERS database	12
Cardiovascular adverse events in patients with HER2-positive breast cancer treated with trastuzumab-drug conjugates : a Bayesian disproportional real world study for signal detection leveraging the FD	12
Influence factors of metronidazole-related CNS disorders: an analysis of the Japan adverse drug event report and FDA adverse event reporting system	12
Anticoagulant-associated calciphylaxis: analysis of USFDA adverse event report system and clinical feature analysis of reported cases	12
Safety considerations for drugs newly approved for treating acute myeloid leukemia	11
Current safety concerns about the use of antiseizure medications in pregnancy	11
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety	11
A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system	11
Antibody-drug conjugates-related interstitial lung diseases: data mining of the FAERS database	11

Adverse events associated with acute pancreatitis caused by immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database	11
Long-term safety profile and secondary effectiveness of canakinumab in pediatric rheumatic diseases: a single-center experience	11
How do safety warnings on medicines affect prescribing?	11
Comparative effectiveness and safety of drug therapy for chronic urticaria: a network meta-analysis and risk-benefit assessment	11
Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge	11
Assessment of adverse events of tasimelteon: a real-world pharmacovigilance study based on FAERS	11
Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS)	11
Drug-induced hyperacusis: a disproportionality analysis of the FAERS database	10
Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies	10
Adverse events of direct factor Xa inhibitors: a disproportionality analysis of the FAERS database	10
Congenital anomalies associated with the use of cardiovascular drugs during pregnancy: a large-scale data analysis from the FAERS database	10
Updated insights on levetiracetam-associated severe cutaneous adverse reactions: a real-world pharmacovigilance analysis	10
Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database	10
Adverse event profile of ocular injury associated with JAK inhibitors in patients with rheumatoid arthritis: a disproportionality analysis	10
Hemorrhage profile associated with immune checkpoint inhibitors: a systematic review and a real-world study based on the FAERS database	10
Adverse events associated with inclisiran: a real-world disproportionality analysis based on the FAERS database	9
The importance and utility of post market drug safety monitoring in cancer therapy	9
Potential drugs for reducing the occurrence of immune checkpoint inhibitor-induced interstitial lung disease: an exploratory study using the JADER and FAERS databases	9
Impact of preoperative pharmaceutical care consultation on medication errors in surgical patients: a comprehensive analysis	9
Adverse event signal analysis of type Ib MET tyrosine kinase inhibitors based on food and drug administration adverse event reporting system	9
Will the future of pharmacovigilance be more automated?	9
A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab	9
Analysis of the relationship between histamine H1 receptor antagonists and broad dementia events using the FAERS, JADER, and CVAR databases	9
Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network	9
Detection of risk signals for ustekinumab in the real world using the FDA Adverse Event Reporting System (FAERS)	9
Treating psychosis in people with Parkinson’s disease	9
Generic pharmaceuticals, regulatory aspects, bioequivalence investigation, and perception	8
Drug-induced dementia: a pharmacovigilance analysis of the FAERS database	8
A review on side effect management of second-generation antipsychotics to treat schizophrenia: a drug safety perspective	8
Reply to Letter to the Editor regarding “Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database”	8
Safety profiles of tetracycline-class drugs: a pharmacovigilance analysis of the FAERS database	8
Completeness of pharmaceutical industry insulin adverse event reports from Africa and the Middle East	8
Investigating bleeding adverse events associated with BTK inhibitors in the food and drug administration adverse event reporting system (FAERS)	8
Skin cancer associated with calcineurin inhibitors treatment: analysis of FAERS database	8
COVID-19 vaccine safety studies- the need for a third group for extended monitoring	8
Comparing musculoskeletal and connective tissue disorder risks of teriparatide and abaloparatide in osteoporosis: an analysis based on FDA adverse event reporting system (FAERS)	8
Safety evaluation of ILaris: a real-world analysis of adverse events based on the FAERS database	8
Biosimilars and immunogenicity: a matter of concern?	8
Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system	7
Real-world safety evaluation of brivaracetam: insights from the US FDA Adverse Event Reporting System	7
Safety of medications for hereditary angioedema during pregnancy and lactation	7
The efficacy and safety of Capivasertib (AZD5363) in the treatment of patients with solid tumor: a systematic review and meta-analysis of randomized clinical trials	7
Contributory factors and patient harm including deaths associated direct acting oral anticoagulants (DOACs) medication incidents: evaluation of real world data reported to the National Reporting and L	7
Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System databas	7
Dupilumab in real-life settings: a review of adverse events and their pathogenesis	7
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients	7
Risk factors analysis and construction of predictive models for acute kidney injury in overweight patients receiving vancomycin treatment	7
Comparison of four criteria for potentially inappropriate medications in older patients with newly diagnosed non-small cell lung cancer	7
Seizures associated with antibiotics: a real-world disproportionality analysis of FAERS database	7
Effects of adding adjuvants to propofol on the post-anesthesia cognitive function in patients undergoing gastroscopy/colonoscopy: a systematic review and meta-analysis	7
An update on the safety of ixazomib for the treatment of multiple myeloma	7
Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges	7
Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database	7
The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands	7
Ocular adverse events of cenegermin used in neurotrophic keratopathy: an analysis of the FDA adverse event reporting system database	7
Hepatobiliary disorders and Direct-Acting Antiviral (DAA) therapies: real-world evidence and insights from the EudraVigilance database	7
Study on analgesic-induced endocrine gland damage and its potential mechanisms	7
Safety evaluation of secukinumab in pediatric patients with plaque psoriasis	7
Liver toxicity in oncology trials and beyond: a simplified concept for management of hepatocellular drug-induced liver injury in patients with abnormal baseline liver tests	7
Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior lite	7
Signal mining and gender differences analysis of adverse events in NMIBC treatment with gemcitabine and BCG bladder instillation based on the FAERS database	6
Barriers and facilitators for systematically registering adverse drug reactions in electronic health records: a qualitative study with Dutch healthcare professionals	6
Adverse events associated with inclisiran: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS)	6
The impact of the COVID-19 pandemic on adverse events associated with ACEIs and ARBs: a real-world analysis using the FDA adverse event reporting system	6
Comparative evaluation of adverse drug reactions for tenofovir alafenamide and tenofovir disoproxil fumarate using the FAERS Database: a disproportionality analysis	6
Drug-induced Stevens-Johnson syndrome: a disproportionality analysis from the pharmacovigilance database of the World Health Organization	6
Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials	6
Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system	6
Oral isotretinoin for acne: a complete overview	6
Correction	6
Meeting report: an exploration into the scientific and regulatory aspects of pharmaceutical drug quality in the United States	6
Drug-induced nephrolithiasis: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System	6
A new paradigm in adverse drug reaction reporting: consolidating the evidence for an intervention to improve reporting	6
Opioid-related adverse drug events in surgical patients: risk factors and association with clinical outcomes	6
COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formula	6
A real-world pharmacovigilance study of blinatumomab based on the FDA adverse event reporting system	6
Intraocular inflammation as a major adverse event of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: from clinical trials to real-world practice	6
Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study	6
Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS)	6
Postmarketing safety of [ 177 Lu]Lu-PSMA-617 radioligand therapy for prostate cancer: a disproportionality analysis of the FDA adverse event reporting system	6

Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity	6
Definition of treatment resistant psoriasis and related safety concerns	6
Letter to the Editor in response to: “Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database”	6
Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?	6
The therapeutic potential of psilocybin: a systematic review	6
Post-marketing safety assessment of constipation drugs: a real-world pharmacovigilance study based on FAERS database	5
An umbrella review of systematic reviews on contributory factors to medication errors in health-care settings	5
Neural dysfunction, inflammatory disorder, and metabolic interference feature in amantadine-related adverse drug events: a perspective from FAERS and network toxicology	5
A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis	5
Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer’s disease: a systematic review and meta-analysis	5
Analyzing the patterns of adverse drug reactions due to anti-infectives from large-scale nationwide database in Thailand	5
Comparison of safety of acetaminophen and ibuprofen in minors: based on the FAERS database	5
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis	5
Safety assessment of tafamidis: a real-world adverse event analysis from the FAERS database	5
A comparative analysis of the safety profiles between inclisiran and other PCSK9 inhibitors from real-world evidence – what have we learned recently?	5
A retrospective study to evaluate Hy’s Law, DrILTox ALF score, Robles-Diaz model, and a new logistic regression model for predicting acute liver failure in Chinese patients with drug-induced liver inj	5
Management of refractory checkpoint inhibitor-induced colitis	5
Cyclin-dependent kinase 4/6 inhibitor-associated pulmonary toxicity: a disproportionality analysis from 2015 to 2023 based on the FAERS database	5
Hematopoietic adverse events associated with PARP inhibitors: A FAERS database study	5
PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS)	5
The safety and efficacy of sugammadex for reversing neuromuscular blockade in younger children and infants	5
Examining the safety of belimumab, especially in children: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database	5
The safety of available pharmacotherapy for stroke prevention in atrial fibrillation	5
Approved treatments for neovascular age-related macular degeneration: current safety and future directions	5
Potential side effects of currently available pharmacotherapies in male lower urinary tract symptoms suggestive of benign prostatic hyperplasia	5
Incidence, clinical characteristics and related drugs analyzing of drug-induced movement disorders in 102914 inpatients: a retrospective real-world study	5
Cardiovascular adverse events associated with EGFR and HER2 dual TKIs: a pharmacovigilance study based on the FAERS database	5
Characteristics of adverse drug reactions induced by flutamide and bicalutamide: a real-world pharmacovigilance study using FAERS	5
Pharmacovigilance insights into drug-induced cystitis: analysis of FDA data from 2004 to 2024	5
Correction	5
A real-world pharmacovigilance case/non-case study of FDA adverse event reporting system events for mannitol	5
Incidence and risk of treatment-related fatal adverse events in cancer patients treated with antibody conjugated drugs: a systematic review and meta-analysis of randomized controlled trials	5
Assessment of safety profile of ivabradine in real-world scenario using FDA adverse event reporting system database	5
Reviewing the evidence surrounding preservative-free tafluprost/timolol fixed-dose combination therapy in open-angle glaucoma and ocular hypertension management: a focus on efficacy, safety, and toler	5
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review	5
Ten years-experience of sunitinib in the treatment of advanced pan-NETs: an update on safety profile	5
Post-marketing safety of panitumumab: a real-world pharmacovigilance study	5
Concomitant use of sodium-glucose co-transporter 2 inhibitors and metformin and the risk of osteomyelitis reporting: a disproportionality analysis based on FAERS database	5
Pre- and post-operative safety considerations for patients undergoing percutaneous nephrolithotomy	5
Risk of serious skin and subcutaneous tissue disorders for nimesulide among the pediatric population: a jeopardy identified through the analysis of global individual case safety reports	5
Adverse event profile of setmelanotide in obesity: an integrated assessment and systematic review using disproportionality analysis, case reports and meta-analysis	4
Post-marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database	4
Adverse drug event reporting among women: uncovering disparities in underserved communities	4
New exploration of signal detection of Regional Risks from the perspective of data mining: a pharmacovigilance analysis based on spontaneous reporting data in Zhenjiang, China	4
Adverse effects associated with antipsychotic use in older adults	4
Major adverse events associated with lipid reduction in inclisiran: a pharmacovigilance research of the FAERS database	4
Immune checkpoint inhibitor-related gastrointestinal adverse events: a disproportionality analysis based on the FAERS database	4
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis	4
Infectious complications associated with immune and targeted anti-cancer therapies: a retrospective study of the FDA adverse events reporting system (FAERS)	4
Comparative safety review of antithrombotic treatment options for patients with atrial fibrillation undergoing percutaneous coronary intervention	4
Improving the risk-to-benefit ratio of inhaled corticosteroids through delivery and dose: current progress and future directions	4
Clozapine-treated patients and myocardial infarction in adults: a pharmacovigilance study in VigiBase interpreted in the context of the literature	4
Assessment of Riociguat-related adverse events: a disproportionality analysis utilizing the FDA adverse event reporting system database	4
Real-world analysis of levetiracetam-associated rhabdomyolysis: insights from the FDA adverse event reporting system	4
Severe cutaneous adverse reactions due to antibiotics therapy: a pharmacovigilance analysis of FDA adverse event reporting system events	4
Actual drug-related harms in residential aged care facilities: a narrative review	4
The evolution of real-world evidence in healthcare decision making	4
Constipation-predominant irritable bowel syndrome treatment options Linaclotide, Lubiprostone, Plecanatide, and Tenapanor: analysis of the FDA Adverse Event Reporting System (FAERS) database	4
Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation	4
Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related	4
An overview of methodological flaws of real-world studies investigating drug safety in the post-marketing setting	4
Pulmonary adverse events associated with amiodarone: a real-world pharmacovigilance study based on the FDA adverse event reporting system	4
Evaluating the Impact of Black Box Warning Updates on the Reporting of Drug-Related Adverse Events: a Cross Sectional Study of the FAERS Database	4
Serotonin 5-HT 2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents	4
Suspected statin-related adverse drug reactions: analysis of spontaneous reports in Hubei Province, China (2014–2022)	4
Dalbavancin in the treatment of acute bacterial skin and skin structure and other infections: a safety evaluation	4
Identification of novel signal of Raynaud’s phenomenon with Calcitonin Gene-Related Peptide(CGRP) antagonists using data mining algorithms and network pharmacological approaches	4
Adverse drug reactions of intravesical instillation therapy for bladder cancer: based on FDA adverse event reporting system	4
Ondansetron induced blindness: a pharmacovigilance database study	4
What does real-world data reveal about cangrelor’s safety? An analysis of FDA adverse event reporting system (FAERS) database	4
Drug-induced hypoglycemia: a disproportionality analysis of the FAERS database	4
Central serous chorioretinopathy secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS)	4
Use of medroxyprogesterone acetate and risk of meningiomas: a comparative safety study	4
Safety profile of lasmiditan in patients with migraine in an Asian population	4
Anaphylactic risk associated with iodinated and gadolinium-based contrast media	4
Evaluation of the safety and efficacy of biosimilar recombinant growth hormone in children with growth hormone deficiency: non-inferiority, randomized, parallel, multicentric and Phase III trial	4
Venous thromboembolism risk with Janus kinase inhibitors: Is it a class wide effect?	4
Safety of PARP inhibitors as maintenance therapy in ovarian cancer	4
Quality of life in ovarian cancer patients treated with bevacizumab: a meta-analysis	4
Influence of prior treatment protocol on intravitreal dexamethasone implant behavior in patients with diabetic macular edema in real-world practice	4
Appropriateness of psychopharmacological therapies to psychiatric diagnoses in persons with autism spectrum disorder with or without intellectual disabilities: a cross-sectional analytic study	4
Safety analysis of fluoroquinolone drugs in elderly patients over 65 based on FAERS	4
Mining and analysis of adverse events associated with aducanumab: a real-world study using FDA Adverse Event Reporting System database	4
Mining and disproportionality analysis of adverse events signals for naltrexone based on real-world data from the FAERS database	4
Flu vaccination in multiple sclerosis patients: a monocentric prospective vaccine-vigilance study	4
Mining and analysis of amphotericin B adverse reaction signals: a real-world study based on the FAERS database	4
Priapism associated with anti-seizure medications: a pharmacovigilance study and a review of published cases	4